- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00566761
Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (MECROV)
November 30, 2007 updated by: Asociación para Evitar la Ceguera en México
Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion
Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Comparison of two groups with different treatment with registrations of outcome in BCVA and complications
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carmen Conzalez-Mijares, Physician
- Phone Number: 5517638245
- Email: cacegomi@hotmail.com
Study Locations
-
-
Coyoacan
-
Mexico city, Coyoacan, Mexico, 04030
- Recruiting
- Asociación Para Evitar la Ceguera en México
-
Contact:
- Retina Department
- Phone Number: 1171 5510841400
- Email: retinamex@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Macular edema secondary to central retinal vein occlusion
- BCVA worse than 20/40
- Central macular >250 mc with OCT
Exclusion Criteria:
- Diabetic retinopathy or other retinopathy
- Media opacity that does not allow following
- steroid responder
- diagnosed glaucoma or IOP > 21 mmHg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in Best corrected visual acuity and macular edema measured with OCT
Time Frame: Follow up to 3 , 6 and 12 months
|
Follow up to 3 , 6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Report treatment complications
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Carmen Gonzalez-Mijares, Physician, Asociación Para Evitar la Ceguera en México
- Study Director: Hugo Quiroz-Mercado, Retinologyst, Asociación Para Evitar la Ceguera en México
- Study Chair: Juan Manuel Jimenez Sierra, Retinologyst, Asociación Para Evitar la Ceguera en México
- Study Chair: MA Martinez-Castellanos, Physician, Asociación Para Evitar la Ceguera en México
- Study Chair: Octavio Burgos Vejar, Physician, Asociación Para Evitar la Ceguera en México
- Study Chair: Raul Velez-Montoya, Physician, Asociación Para Evitar la Ceguera en México
- Study Chair: Ma de Lourdes Lopez Ramos, Physician, Asociación Para Evitar la Ceguera en México
- Study Chair: Omar Honerlager, preresident, Asociación Para Evitar la Ceguera en México
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Study Completion (Anticipated)
March 1, 2008
Study Registration Dates
First Submitted
November 30, 2007
First Submitted That Met QC Criteria
November 30, 2007
First Posted (Estimate)
December 4, 2007
Study Record Updates
Last Update Posted (Estimate)
December 4, 2007
Last Update Submitted That Met QC Criteria
November 30, 2007
Last Verified
November 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Edema
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Triamcinolone
Other Study ID Numbers
- MECRVO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
The Emmes Company, LLCNational Eye Institute (NEI); University of California, DavisActive, not recruitingCentral Retinal Vein OcclusionUnited States
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenCompleted
-
Centre Hospitalier Intercommunal CreteilCompletedCentral Retinal Vein OcclusionFrance
-
Fondation Ophtalmologique Adolphe de RothschildBayerActive, not recruiting
Clinical Trials on bevacizumab and triamcinolone
-
Rubens Belfort Jr.CompletedDiabetic Macular EdemaBrazil
-
Shahid Beheshti University of Medical SciencesUnknownNeovascular Age-Related Macular DegenerationIran, Islamic Republic of
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Shahid Beheshti University of Medical SciencesUnknownDiabetic Macular EdemaIran, Islamic Republic of
-
Hospital Clinic of BarcelonaTerminated
-
Yonsei UniversityWithdrawnMacular DegenerationKorea, Republic of
-
Yeungnam University College of MedicineCompletedBranch Retinal Vein OcclusionKorea, Republic of
-
University of Sao PauloCompletedDiabetic Macular Edema
-
Universidade Federal de GoiasCompleted
-
Shahid Beheshti University of Medical SciencesUnknownNeovascular Age-Related Macular DegenerationIran, Islamic Republic of